JP2011006431A5 - - Google Patents

Download PDF

Info

Publication number
JP2011006431A5
JP2011006431A5 JP2010177518A JP2010177518A JP2011006431A5 JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5 JP 2010177518 A JP2010177518 A JP 2010177518A JP 2010177518 A JP2010177518 A JP 2010177518A JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5
Authority
JP
Japan
Prior art keywords
ataxia
adenosine
medicament
prevention
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010177518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011006431A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011006431A publication Critical patent/JP2011006431A/ja
Publication of JP2011006431A5 publication Critical patent/JP2011006431A5/ja
Pending legal-status Critical Current

Links

JP2010177518A 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用 Pending JP2011006431A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43532102P 2002-12-19 2002-12-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005510511A Division JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013013961A Division JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Publications (2)

Publication Number Publication Date
JP2011006431A JP2011006431A (ja) 2011-01-13
JP2011006431A5 true JP2011006431A5 (enExample) 2011-09-15

Family

ID=34572685

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2010177518A Pending JP2011006431A (ja) 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Country Status (15)

Country Link
US (2) US7414058B2 (enExample)
EP (3) EP2269596A3 (enExample)
JP (3) JP2006514697A (enExample)
CN (2) CN100415217C (enExample)
AT (1) ATE490775T1 (enExample)
AU (2) AU2003304527B2 (enExample)
BR (1) BR0317436A (enExample)
DE (1) DE60335294D1 (enExample)
ES (1) ES2354875T3 (enExample)
MX (1) MXPA05006790A (enExample)
NO (1) NO20053509L (enExample)
NZ (1) NZ540493A (enExample)
TW (1) TWI331036B (enExample)
WO (1) WO2005044245A1 (enExample)
ZA (1) ZA200504478B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287748B6 (sk) * 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
ES2354875T3 (es) * 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TWI355381B (en) * 2003-04-23 2012-01-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
NZ550591A (en) 2004-04-21 2010-10-29 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
MX2007003381A (es) 2004-09-22 2007-04-27 Lundbeck & Co As H Derivados de 2-acilaminotiazol.
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
WO2006132275A1 (ja) * 2005-06-07 2006-12-14 Kyowa Hakko Kogyo Co., Ltd. 運動障害の予防および／または治療剤
CA2622741A1 (en) * 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US8222259B2 (en) 2008-03-04 2012-07-17 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
US8473582B2 (en) * 2009-12-16 2013-06-25 International Business Machines Corporation Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN105025899B (zh) * 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
BR112019027446A2 (pt) * 2017-06-30 2020-07-07 Ryvu Therapeutics S.A. moduladores do receptor de adenosina a2a
JP7391022B2 (ja) 2017-12-19 2023-12-04 インペティス・バイオサイエンシーズ・リミテッド がんの処置のための医薬組成物
AU2019205661B2 (en) 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
EP0666079B1 (en) 1993-07-27 2001-11-07 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5933964A (en) * 1996-07-17 1999-08-10 Wahl Clipper Corporation Cutter blade for hair clippers
WO1999026627A1 (en) 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
SK287748B6 (sk) * 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE60231386D1 (de) * 2001-04-09 2009-04-16 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
CN1692116A (zh) 2001-11-30 2005-11-02 先灵公司 腺苷A2a受体拮抗剂
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
EP1453836B1 (en) * 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
PT2942082T (pt) * 2002-01-28 2019-06-06 Kyowa Hakko Kogyo Kk Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
CN1671390A (zh) * 2002-08-30 2005-09-21 协和发酵工业株式会社 用于治疗多动腿综合症或相关疾病的腺苷a2a受体拮抗剂
ES2354875T3 (es) * 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
TWI355381B (en) * 2003-04-23 2012-01-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri

Similar Documents

Publication Publication Date Title
JP2011006431A5 (enExample)
HUS2200018I1 (hu) Drospirenont tartalmazó gyógyszerkészítmény, fogamzásgátlóként történõ alkalmazásra
LT3632919T (lt) Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
DK2877574T3 (da) Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ITMI20111404A1 (it) Supporto per articolazioni umane.
EP2647381A4 (en) MELTING TABLET
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
EP3038466A4 (en) 2,2-difluorodioxolo a2a receptor antagonists
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BR112012018402A2 (pt) "produto refratário com elevado teor de zircônio".
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EP2533763C0 (de) Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
PL2623499T3 (pl) Pochodne 1,2,4-triazolonu
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112012021455A2 (pt) formulação farmacêutica ou nutracêutica.
FR2953410B1 (fr) Compositions antivirales pharmaceutiques ou veterinaires
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo